<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="http://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 http://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="5944937d-4840-4562-a5ae-30825414ce0b"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <effectiveTime value="20100722"/>
   <setId root="fe8480c4-b176-45ae-b4d6-fa59912fe286"/>
   <versionNumber value="4"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="194123980" root="1.3.6.1.4.1.519.1"/>
            <name>Physicians Total Care, Inc.</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="194123980" root="1.3.6.1.4.1.519.1"/>
                        <name>Physicians Total Care, Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C73607" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="relabel"/>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C73606" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="repack"/>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="13d44b75-79ff-4c17-a86e-c520c7e9170d"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL listing data elements section"/>
               <effectiveTime value="20101109"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="54868-5650" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Meloxicam<suffix/>
                        </name>
                        <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Meloxicam</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asEquivalentEntity classCode="EQUIV">
                           <code code="C64637" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <definingMaterialKind>
                              <code code="29300-124" codeSystem="2.16.840.1.113883.6.69"/>
                           </definingMaterialKind>
                        </asEquivalentEntity>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="7.5" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="VG2QF83CGL" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MELOXICAM</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="VG2QF83CGL" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>MELOXICAM</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="68401960MK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSPOVIDONE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CELLULOSE, MICROCRYSTALLINE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="FZ989GH94E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POVIDONE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="B22547B95K" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TRISODIUM CITRATE DIHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="30" unit="1">
                                 <translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="54868-5650-0" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="60" unit="1">
                                 <translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="54868-5650-1" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="100" unit="1">
                                 <translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="54868-5650-2" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="90" unit="1">
                                 <translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="54868-5650-3" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="10" unit="1">
                                 <translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="54868-5650-4" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="20" unit="1">
                                 <translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="54868-5650-5" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="15" unit="1">
                                 <translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="54868-5650-6" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PLASTIC"/>
                           </containerPackagedProduct>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20060807"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA077927" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48330" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="yellow" xsi:type="CE">
                              <originalText>Light Yellow</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND" xsi:type="CE">
                              <originalText>Round</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">U;L;7;5</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="7" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="54868-5651" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Meloxicam<suffix/>
                        </name>
                        <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Meloxicam</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asEquivalentEntity classCode="EQUIV">
                           <code code="C64637" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <definingMaterialKind>
                              <code code="29300-125" codeSystem="2.16.840.1.113883.6.69"/>
                           </definingMaterialKind>
                        </asEquivalentEntity>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="15" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="VG2QF83CGL" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MELOXICAM</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="VG2QF83CGL" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>MELOXICAM</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="68401960MK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSPOVIDONE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CELLULOSE, MICROCRYSTALLINE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="FZ989GH94E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POVIDONE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="B22547B95K" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TRISODIUM CITRATE DIHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="30" unit="1">
                                 <translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="54868-5651-0" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="100" unit="1">
                                 <translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="54868-5651-1" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="60" unit="1">
                                 <translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="54868-5651-2" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="90" unit="1">
                                 <translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="54868-5651-3" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PLASTIC"/>
                           </containerPackagedProduct>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="15" unit="1">
                                 <translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="54868-5651-4" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PLASTIC"/>
                           </containerPackagedProduct>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20060807"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA077927" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48330" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="yellow" xsi:type="CE">
                              <originalText>Light Yellow</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OVAL" xsi:type="CE">
                              <originalText>Oblong</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">U;L;15</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="11" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section>
               <id root="922497cd-705f-473c-a0b5-6c72c3bf301f"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">ATTENTION DISPENSER: Accompanying Medication Guide <content styleCode="underline">must</content> be dispensed with this product.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Prescribing Information</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">WARNING</content>
                  </paragraph>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>Cardiovascular Risk<list listType="unordered" ID="ie0006fca-ea00-47cb-84a8-e6f7963e10a9">
                     <item>NSAIDs may cause an increased risk of serious cardiovascular thrombotic 
events, myocardial infarction, and stroke, which can be fatal. This risk may 
increase with duration of use. Patients with cardiovascular disease or risk 
factors for cardiovascular disease may be at greater risk (see <content styleCode="bold">
                           <linkHtml href="#section-"> WARNINGS </linkHtml>
                        </content>and <content styleCode="bold">
                           <linkHtml href="#section-"> CLINICAL TRIALS</linkHtml>
                        </content>).</item>
                     <item>Meloxicam is contraindicated for the treatment of peri-operative pain in the 
setting of coronary artery bypass graft (CABG) surgery (see <linkHtml href="#section-"> WARNINGS</linkHtml> ).</item>
                  </list>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>Gastrointestinal Risk<list listType="unordered" ID="i093c0d7d-a241-493e-8558-9570b44342b7">
                     <item>NSAIDs cause an increased risk of serious gastrointestinal adverse events 
including bleeding, ulceration, and perforation of the stomach or intestines, 
which can be fatal. These events can occur at any time during use and without 
warning symptoms. Elderly patients are at greater risk for serious 
gastrointestinal events (see <content styleCode="bold">
                           <linkHtml href="#section-"> WARNINGS</linkHtml>
                        </content>).</item>
                  </list>
               </text>
               <effectiveTime value="20110221"/>
            </section>
         </component>
         <component>
            <section>
               <id root="c5d68d5b-4bec-4df8-9ca8-e5f306f1056d"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>DESCRIPTION</title>
               <text>
                  <paragraph>Meloxicam, an oxicam derivative, is a member of the enolic acid group of 
nonsteroidal anti-inflammatory drugs (NSAIDs). Each pastel yellow Meloxicam 
tablet USP contains 7.5 mg or 15 mg meloxicam for oral administration. Meloxicam 
is chemically designated as 4-hydroxy-2-methyl-<content styleCode="italics">N</content>-(5-methyl-2-thiazolyl)-<content styleCode="italics">2H</content>-1,2-benzothiazine-3-carboxamide-1,1-dioxide. The 
molecular weight is 351.4. Its empirical formula is C<sub>14</sub>H<sub>13</sub>N<sub>3</sub>O<sub>4</sub>S<sub>2</sub> and it has the following structural 
formula.</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM1"/>
                  </paragraph>
                  <paragraph>
                     <linkHtml href=""/>Meloxicam is a pastel yellow solid, practically insoluble in 
water, with higher solubility observed in strong acids and bases. It is very 
slightly soluble in methanol. Meloxicam has an apparent partition coefficient 
(log P)app = 0.1 in <content styleCode="italics">n</content>-octanol/buffer pH 7.4. 
Meloxicam has pKa values of 1.1 and 4.2.</paragraph>
                  <paragraph>Meloxicam is available as a tablet for oral administration containing 7.5 mg 
or 15 mg meloxicam.</paragraph>
                  <paragraph>The inactive ingredients in Meloxicam tablets USP include colloidal silicon 
dioxide, crospovidone, lactose monohydrate, magnesium stearate, microcrystalline 
cellulose, povidone and sodium citrate dihydrate.</paragraph>
               </text>
               <effectiveTime value="20100722"/>
               <component>
                  <observationMedia classCode="OBS" moodCode="EVN" ID="MM1">
                     <text>image of chemical structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="chemical structure.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="f33e2e67-e1b5-4caa-863f-4b9a7d95bdaa"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>CLINICAL PHARMACOLOGY</title>
               <text>
                  <paragraph>Enter section text here</paragraph>
               </text>
               <effectiveTime value="20100722"/>
               <component>
                  <section>
                     <id root="10e1639c-8710-4c87-b0e4-92389cbc0b40"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>Mechanism of Action</title>
                     <text>
                        <paragraph>Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) that exhibits 
anti-inflammatory, analgesic, and antipyretic activities in animal models. The 
mechanism of action of meloxicam, like that of other NSAIDs, may be related to 
prostaglandin synthetase (cyclo-oxygenase) inhibition.</paragraph>
                     </text>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="b9f35645-730b-4bcd-939d-e7526c1991a6"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>Pharmacokinetics</title>
                     <text>
                        <paragraph>
                           <linkHtml href=""/>
                           <content styleCode="italics">Absorption</content>
                        </paragraph>
                        <paragraph>The absolute bioavailability of meloxicam capsules was 89% following a single 
oral dose of 30 mg compared with 30 mg IV bolus injection. Following single 
intravenous doses, dose-proportional pharmacokinetics were shown in the range of 
5 mg to 60 mg. After multiple oral doses the pharmacokinetics of meloxicam 
capsules were dose-proportional over the range of 7.5 mg to 15 mg. Mean C<sub>max</sub> was achieved within four to five hours after a 7.5 mg 
meloxicam tablet was taken under fasted conditions, indicating prolonged drug 
absorption. With multiple dosing, steady state concentrations were reached by 
Day 5. A second meloxicam concentration peak occurs around 12 to 14 hours 
post-dose suggesting biliary recycling.</paragraph>
                        <table width="100%" ID="ieeed0b48-4f1e-4f72-8abf-127619df4e0d">
                           <caption>Table 1 Single Dose and Steady State Pharmacokinetic Parameters for Oral 7.5 mg and 15 mg Meloxicam (Mean and % CV)1 </caption>
                           <thead>
                              <tr>
                                 <th>
                                    <br/>
                                 </th>
                                 <th>
                                    <br/>
                                 </th>
                                 <th>Steady State<br/>
                                 </th>
                                 <th>
                                    <br/>
                                 </th>
                                 <th>
                                    <br/>
                                 </th>
                                 <th>Single Dose<br/>
                                 </th>
                                 <th>
                                    <br/>
                                 </th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr>
                                 <td>
                                    <content styleCode="bold">Pharmacokinetic<br/>Parameters<br/>(%CV)<br/>
                                    </content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">Healthy<br/>Male Adults<br/>(Fed)<sup>2</sup>
                                       <br/>
                                    </content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">Elderly<br/>Males<br/>(Fed)<sup>2</sup>
                                       <br/>
                                    </content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">Elderly<br/>Females<br/>(Fed)<sup>2</sup>
                                       <br/>
                                    </content>
                                 </td>
                                 <td>
                                    <br/>
                                 </td>
                                 <td>
                                    <content styleCode="bold">Renal<br/>Failure<br/>(Fasted)<br/>
                                    </content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">Hepatic<br/>Insufficiency<br/>(Fasted)<br/>
                                    </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>
                                    <br/>
                                 </td>
                                 <td>
                                    <content styleCode="bold">7.5 mg<sup>3</sup>
                                       <br/>tablets<br/>
                                    </content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">15 mg<br/>Capsules<br/>
                                    </content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">15 mg<br/>Capsules<br/>
                                    </content>
                                 </td>
                                 <td>
                                    <br/>
                                 </td>
                                 <td>
                                    <content styleCode="bold">15 mg<br/>Capsules<br/>
                                    </content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">15 mg<br/>Capsules<br/>
                                    </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>
                                    <content styleCode="bold">N</content>
                                    <br/>
                                 </td>
                                 <td>
                                    <content styleCode="bold">18</content>
                                    <br/>
                                 </td>
                                 <td>
                                    <content styleCode="bold">5</content>
                                    <br/>
                                 </td>
                                 <td>
                                    <content styleCode="bold">8</content>
                                    <br/>
                                 </td>
                                 <td>
                                    <content styleCode="bold"/>
                                    <br/>
                                 </td>
                                 <td>
                                    <content styleCode="bold">12</content>
                                    <br/>
                                 </td>
                                 <td>
                                    <content styleCode="bold">12</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td>C<sub>max          </sub>[ug/mL]<br/>
                                 </td>
                                 <td>1.05 (20)<br/>
                                 </td>
                                 <td>2.3 (59)<br/>
                                 </td>
                                 <td>3.2 (24)<br/>
                                 </td>
                                 <td>
                                    <br/>
                                 </td>
                                 <td>0.59 (36)<br/>
                                 </td>
                                 <td>0.84 (29)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td>t<sub>max            </sub>[h]<br/>
                                 </td>
                                 <td>4.9 (8)<br/>
                                 </td>
                                 <td>5 (12)<br/>
                                 </td>
                                 <td>6 (27)<br/>
                                 </td>
                                 <td>     <br/>
                                 </td>
                                 <td>4 (65)<br/>
                                 </td>
                                 <td>10 (87)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td>t<sub>1</sub>
                                    <sub>/</sub>
                                    <sub>2              </sub>[h]</td>
                                 <td>20.1 (29)<br/>
                                 </td>
                                 <td>21 (34)<br/>
                                 </td>
                                 <td>24 (34)<br/>
                                 </td>
                                 <td>
                                    <br/>
                                 </td>
                                 <td>18 (46)<br/>
                                 </td>
                                 <td>16 (29)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td>CL/f       [mL/min]<br/>
                                 </td>
                                 <td>8.8 (29)<br/>
                                 </td>
                                 <td>9.9 (76)<br/>
                                 </td>
                                 <td>5.1 (22)<br/>
                                 </td>
                                 <td>
                                    <br/>
                                 </td>
                                 <td>19 (43)<br/>
                                 </td>
                                 <td>11 (44)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td>Vz/f<sup>4         </sup>[L]<sup/>
                                 </td>
                                 <td>14.7 (32)<br/>
                                 </td>
                                 <td>15 (42)<br/>
                                 </td>
                                 <td>10 (30)<br/>
                                 </td>
                                 <td>
                                    <br/>
                                 </td>
                                 <td>26 (44)<br/>
                                 </td>
                                 <td>14 (29)<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <sup>1</sup> The parameter values in the Table are from various studies <br/>
                        <sup>2</sup> not under high fat conditions<br/>
                        <sup>3</sup> Meloxicam tablets<br/>
                        <sup>4</sup> Vz/f =Dose/(AUC•Kel)<br/>
                        <br/>
                        <paragraph>
                           <linkHtml href=""/>
                           <content styleCode="italics">Food and Antacid Effects</content>
                        </paragraph>
                        <paragraph>Administration of meloxicam capsules following a high fat breakfast (75 g of 
fat) resulted in mean peak drug levels (i.e., C<sub>max</sub>) being 
increased by approximately 22% while the extent of absorption (AUC) was 
unchanged. The time to maximum concentration (T<sub>max</sub>) was 
achieved between 5 and 6 hours. No pharmacokinetic interaction was detected with 
concomitant administration of antacids. Based on these results, meloxicam can be 
administered without regard to timing of meals or concomitant administration of 
antacids.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Distribution</content>
                        </paragraph>
                        <paragraph>The mean volume of distribution (Vss) of meloxicam is approximately 10 L. 
Meloxicam is ~ 99.4% bound to human plasma proteins (primarily albumin) within 
the therapeutic dose range. The fraction of protein binding is independent of 
drug concentration, over the clinically relevant concentration range, but 
decreases to ~ 99% in patients with renal disease. Meloxicam penetration into 
human red blood cells, after oral dosing, is less than 10%. Following a 
radiolabeled dose, over 90% of the radioactivity detected in the plasma was 
present as unchanged meloxicam.</paragraph>
                        <paragraph>Meloxicam concentrations in synovial fluid, after a single oral dose, range 
from 40% to 50% of those in plasma. The free fraction in synovial fluid is 2.5 
times higher than in plasma, due to the lower albumin content in synovial fluid 
as compared to plasma. The significance of this penetration is unknown.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Metabolism</content>
                        </paragraph>
                        <paragraph>Meloxicam is almost completely metabolized to four pharmacologically inactive 
metabolites. The major metabolite, 5'-carboxy meloxicam (60% of dose), from 
P-450 mediated metabolism was formed by oxidation of an intermediate metabolite 
5'-hydroxymethyl meloxicam which is also excreted to a lesser extent (9% of 
dose). <content styleCode="italics">In vitro </content>studies indicate that cytochrome 
P-450 2C9 plays an important role in this metabolic pathway with a minor 
contribution of the CYP 3A4 isozyme. Patients’ peroxidase activity is probably 
responsible for the other two metabolites which account for 16% and 4% of the 
administered dose, respectively.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Excretion</content>
                        </paragraph>
                        <paragraph>Meloxicam excretion is predominantly in the form of metabolites, and occurs 
to equal extents in the urine and feces. Only traces of the unchanged parent 
compound are excreted in the urine (0.2%) and feces (1.6%). The extent of the 
urinary excretion was confirmed for unlabeled multiple 7.5 mg doses: 0.5%, 6% 
and 13% of the dose were found in urine in the form of meloxicam, and the 
5'-hydroxymethyl and 5'-carboxy metabolites, respectively. There is significant 
biliary and/or enteral secretion of the drug. This was demonstrated when oral 
administration of cholestyramine following a single IV dose of meloxicam 
decreased the AUC of meloxicam by 50%.</paragraph>
                        <paragraph>The mean elimination half-life (t<sub>1/2</sub>) ranges from 15 
hours to 20 hours. The elimination half-life is constant across dose levels 
indicating linear metabolism within the therapeutic dose range. Plasma clearance 
ranges from 7 to 9 mL/min.</paragraph>
                        <br/>
                     </text>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="270e5131-e024-4e08-b1f3-6a87d9aeda04"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Special Populations</title>
                     <text>
                        <paragraph>
                           <linkHtml href=""/>
                           <content styleCode="italics">Geriatric</content>
                        </paragraph>
                        <paragraph>Elderly males(≥ 65 years of age) exhibited meloxicam plasma concentrations 
and steady state pharmacokinetics similar to young males. Elderly females (≥ 65 
years of age) had a 47% higher AUCss and 32% higher C<sub>max</sub>, 
ss as compared to younger females (≤ 55 years of age) after body weight 
normalization. Despite the increased total concentrations in the elderly 
females, the adverse event profile was comparable for both elderly patient 
populations. A smaller free fraction was found in elderly female patients in 
comparison to elderly male patients.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Gender</content>
                        </paragraph>
                        <paragraph>Young females exhibited slightly lower plasma concentrations relative to 
young males. After single doses of 7.5 mg meloxicam, the mean elimination 
half-life was 19.5 hours for the female group as compared to 23.4 hours for the 
male group. At steady state, the data were similar (17.9 hours vs. 21.4 hours). 
This pharmacokinetic difference due to gender is likely to be of little clinical 
importance. There was linearity of pharmacokinetics and no appreciable 
difference in the C<sub>max</sub> or T<sub>max</sub> 
across genders.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Hepatic Insufficiency</content>
                        </paragraph>
                        <paragraph>Following a single 15 mg dose of meloxicam there was no marked difference in 
plasma concentrations in subjects with mild (Child-Pugh Class I) and moderate 
(Child-Pugh Class II) hepatic impairment compared to healthy volunteers. Protein 
binding of meloxicam was not affected by hepatic insufficiency. No dose 
adjustment is necessary in mild to moderate hepatic insufficiency. Patients with 
severe hepatic impairment (Child-Pugh Class III) have not been adequately 
studied.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Renal Insufficiency</content>
                        </paragraph>
                        <paragraph>Meloxicam pharmacokinetics have been investigated in subjects with different 
degrees of renal insufficiency. Total drug plasma concentrations decreased with 
the degree of renal impairment while free AUC values were similar. Total 
clearance of meloxicam increased in these patients probably due to the increase 
in free fraction leading to an increased metabolic clearance. There is no need 
for dose adjustment in patients with mild to moderate renal failure (CrCL &gt;15 
mL/min). Patients with severe renal insufficiency have not been adequately 
studied. The use of meloxicam in subjects with severe renal impairment is not 
recommended (see <content styleCode="bold">
                              <linkHtml href="#ID27">WARNINGS</linkHtml>
                           </content>, <content styleCode="bold">
                              <linkHtml href="#ID39">Advanced Renal Disease</linkHtml>
                           </content>).</paragraph>
                        <paragraph>
                           <content styleCode="italics">Hemodialysis</content>
                        </paragraph>
                        <paragraph>Following a single dose of meloxicam, the free Cmax plasma concentrations 
were higher in patients with renal failure on chronic hemodialysis (1% free 
fraction) in comparison to healthy volunteers (0.3% free fraction). Hemodialysis 
did not lower the total drug concentration in plasma; therefore, additional 
doses are not necessary after hemodialysis. Meloxicam is not dialyzable.</paragraph>
                     </text>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="44f8d4f9-8c78-463f-bc21-30142f233a03"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>CLINICAL TRIALS</title>
               <text>
                  <paragraph>Enter section text here</paragraph>
               </text>
               <effectiveTime value="20100722"/>
               <component>
                  <section>
                     <id root="92c80e48-b18c-4ae2-800b-f33aeb4480be"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Osteoarthritis and Rheumatoid Arthritis </title>
                     <text>
                        <paragraph>The use of meloxicam for the treatment of the signs and symptoms of 
osteoarthritis of the knee and hip was evaluated in a 12-week double-blind 
controlled trial. Meloxicam (3.75 mg, 7.5 mg and 15 mg daily) was compared to 
placebo. The four primary endpoints were investigator’s global assessment, 
patient global assessment, patient pain assessment, and total WOMAC score (a 
self-administered questionnaire addressing pain, function and stiffness). 
Patients on meloxicam 7.5 mg daily and meloxicam 15 mg daily showed significant 
improvement in each of these endpoints compared with placebo.</paragraph>
                        <paragraph>The use of meloxicam for the management of signs and symptoms of 
osteoarthritis was evaluated in six double-blind, active-controlled trials 
outside the U.S. ranging from 4 weeks to 6 months duration. In these trials, the 
efficacy of meloxicam, in doses of 7.5 mg/day and 15 mg/day, was comparable to 
piroxicam 20 mg/day and diclofenac SR 100 mg/day and consistent with the 
efficacy seen in the U.S. trial. </paragraph>
                        <paragraph>The use of meloxicam for the treatment of the signs and symptoms of 
rheumatoid arthritis was evaluated in a 12-week double-blind, controlled 
multinational trial. Meloxicam (7.5 mg, 15 mg and 22.5 mg daily) was compared to 
placebo. The primary endpoint in this study was the ACR20 response rate, a 
composite measure of clinical, laboratory and functional measures of RA 
response. Patients receiving meloxicam 7.5 mg and 15 mg daily showed significant 
improvement in the primary endpoint compared with placebo. No incremental 
benefit was observed with the 22.5 mg dose compared to the 15 mg dose.</paragraph>
                        <paragraph>Higher doses of meloxicam (22.5 mg and greater) have been associated with an 
increased risk of serious GI events; therefore the daily dose of meloxicam 
should not exceed 15 mg. </paragraph>
                     </text>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="29294687-4f0f-4902-b651-5d15a2932220"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>
                     <linkHtml href=""/>Carefully consider the potential benefits and risks of 
meloxicam and other treatment options before deciding to use meloxicam. Use the 
lowest effective dose for the shortest duration consistent with individual 
patient treatment goals (see <content styleCode="bold">
                        <linkHtml href="#ID27">WARNINGS</linkHtml>
                     </content>).</paragraph>
                  <paragraph>Meloxicam is indicated for relief of the signs and symptoms of osteoarthritis 
and rheumatoid arthritis.</paragraph>
               </text>
               <effectiveTime value="20100722"/>
            </section>
         </component>
         <component>
            <section>
               <id root="0babd7c7-5302-4d3e-838e-24edec4415b4"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>CONTRAINDICATIONS</title>
               <text>
                  <paragraph>
                     <linkHtml href=""/>Meloxicam is contraindicated in patients with known 
hypersensitivity to meloxicam.</paragraph>
                  <paragraph>Meloxicam should not be given to patients who have experienced asthma, 
urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. 
Severe, rarely fatal, anaphylactic-like reactions to NSAIDs have been reported 
in such patients (see <content styleCode="bold">
                        <linkHtml href="#ID27">WARNINGS</linkHtml>
                     </content>, 
<content styleCode="bold">
                        <linkHtml href="#ID41">Anaphylactoid Reactions</linkHtml>
                     </content>, and <content styleCode="bold">
                        <linkHtml href="#ID47">PRECAUTIONS</linkHtml>
                     </content>, <content styleCode="bold">
                        <linkHtml href="#ID56">Pre-existing Asthma</linkHtml>
                     </content>).</paragraph>
                  <paragraph>Meloxicam is contraindicated for the treatment of peri-operative pain in the 
setting of coronary artery bypass graft (CABG) surgery (see <content styleCode="bold">
                        <linkHtml href="#ID27">WARNINGS</linkHtml>
                     </content>).</paragraph>
               </text>
               <effectiveTime value="20100722"/>
            </section>
         </component>
         <component>
            <section>
               <id root="a3e18426-18fa-4580-8096-1a44d67cbc98"/>
               <code code="34071-1" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS SECTION"/>
               <title>WARNINGS</title>
               <text>
                  <paragraph>Enter section text here</paragraph>
               </text>
               <effectiveTime value="20100722"/>
               <component>
                  <section>
                     <id root="7713c765-b276-4beb-9571-fa75a354c695"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Cardiovascular Effects</title>
                     <text>
                        <linkHtml href=""/>Cardiovascular Thrombotic Events<paragraph>
                           <linkHtml href=""/>Clinical trials of several COX-2 selective and nonselective 
NSAIDs of up to three years duration have shown an increased risk of serious 
cardiovascular (CV) thrombotic events, myocardial infarction, and stroke, which 
can be fatal. All NSAIDs, both COX-2 selective and nonselective, may have a 
similar risk. Patients with known CV disease or risk factors for CV disease may 
be at greater risk. To minimize the potential risk for an adverse CV event in 
patients treated with an NSAID, the lowest effective dose should be used for the 
shortest duration possible. Physicians and patients should remain alert for the 
development of such events, even in the absence of previous CV symptoms. 
Patients should be informed about the signs and/or symptoms of serious CV events 
and the steps to take if they occur.</paragraph>
                        <paragraph>There is no consistent evidence that concurrent use of aspirin mitigates the 
increased risk of serious CV thrombotic events associated with NSAID use. The 
concurrent use of aspirin and an NSAID does increase the risk of serious GI 
events (see <content styleCode="bold">
                              <linkHtml href="#ID27">WARNINGS</linkHtml>
                           </content>, <content styleCode="bold">
                              <linkHtml href="#ID35">Gastrointestinal (GI) Effects - Risk of GI 
Ulceration, Bleeding, and Perforation</linkHtml>
                           </content>).</paragraph>
                        <paragraph>Two large, controlled, clinical trials of a COX-2 selective NSAID for the 
treatment of pain in the first 10-14 days following CABG surgery found an 
increased incidence of myocardial infarction and stroke (see <content styleCode="bold">
                              <linkHtml href="#ID25">CONTRAINDICATIONS</linkHtml>
                           </content>).</paragraph>
                        <linkHtml href=""/>
                        <linkHtml href=""/>
                        <linkHtml href=""/>Hypertension<paragraph>
                           <linkHtml href=""/>NSAIDs, including meloxicam can lead to onset of new 
hypertension or worsening of pre-existing hypertension, either of which may 
contribute to the increased incidence of CV events. Patients taking thiazides or 
loop diuretics may have impaired response to these therapies when taking NSAIDs. 
NSAIDs, including meloxicam should be used with caution in patients with 
hypertension. Blood pressure (BP) should be monitored closely during the 
initiation of NSAID treatment and throughout the course of therapy.</paragraph>
                        <linkHtml href=""/>
                        <linkHtml href=""/>
                        <linkHtml href=""/>Congestive Heart Failure and Edema<paragraph>
                           <linkHtml href=""/>Fluid retention and edema have been observed in some 
patients taking NSAIDs. Meloxicam should be used with caution in patients with 
fluid retention, hypertension, or heart failure.</paragraph>
                        <linkHtml href=""/>
                        <linkHtml href=""/>
                        <linkHtml href=""/>Gastrointestinal (GI) Effects - Risk of GI Ulceration, 
Bleeding, and Perforation<paragraph>
                           <linkHtml href=""/>NSAIDs, including meloxicam can cause serious 
gastrointestinal (GI) adverse events including inflammation, bleeding, 
ulceration, and perforation of the stomach, small intestine, or large intestine, 
which can be fatal. These serious adverse events can occur at any time, with or 
without warning symptoms, in patients treated with NSAIDs. Only one in five 
patients, who develop a serious upper GI adverse event on NSAID therapy, is 
symptomatic. Upper GI ulcers, gross bleeding, or perforation caused by NSAIDs, 
occur in approximately 1% of patients treated for 3-6 months, and in about 2-4% 
of patients treated for one year. These trends continue with longer duration of 
use, increasing the likelihood of developing a serious GI event at some time 
during the course of therapy. However, even short-term therapy is not without 
risk.</paragraph>
                        <paragraph>NSAIDs should be prescribed with extreme caution in those with a prior 
history of ulcer disease or gastrointestinal bleeding. Patients with a <content styleCode="italics">prior history of peptic ulcer disease and/or gastrointestinal 
bleeding </content>who use NSAIDs have a greater than 10-fold increased risk for 
developing a GI bleed compared to patients with neither of these risk factors. 
Other factors that increase the risk for GI bleeding in patients treated with 
NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer 
duration of NSAID therapy, smoking, use of alcohol, older age, and poor general 
health status. Most spontaneous reports of fatal GI events are in elderly or 
debilitated patients and therefore, special care should be taken in treating 
this population. </paragraph>
                        <paragraph>To minimize the potential risk for an adverse GI event in patients treated 
with an NSAID, the lowest effective dose should be used for the shortest 
possible duration. Patients and physicians should remain alert for signs and 
symptoms of GI ulceration and bleeding during NSAID therapy and promptly 
initiate additional evaluation and treatment if a serious GI adverse event is 
suspected. This should include discontinuation of the NSAID until a serious GI 
adverse event is ruled out. For high-risk patients, alternate therapies that do 
not involve NSAIDs should be considered.</paragraph>
                     </text>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="3cadcc76-a4a4-435e-97b4-316b82a46802"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Renal Effects</title>
                     <text>
                        <paragraph>Long-term administration of NSAIDs including meloxicam can result in renal 
papillary necrosis, renal insufficiency, acute renal failure, and other renal 
injury. Renal toxicity has also been seen in patients in whom renal 
prostaglandins have a compensatory role in the maintenance of renal perfusion. 
In these patients, administration of a nonsteroidal anti-inflammatory drug may 
cause a dose-dependent reduction in prostaglandin formation and, secondarily, in 
renal blood flow, which may precipitate overt renal decompensation. Patients at 
greatest risk of this reaction are those with impaired renal function, heart 
failure, liver dysfunction, those taking diuretics and ACE inhibitors, 
angiotensin II receptor antagonists, and the elderly. Discontinuation of NSAID 
therapy is usually followed by recovery to the pretreatment state.</paragraph>
                     </text>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="567a88c5-536b-46e5-8882-1230d24faa96"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Advanced Renal Disease</title>
                     <text>
                        <paragraph>No information is available from controlled clinical studies regarding the use 
of meloxicam in patients with advanced renal disease. Therefore, treatment with 
meloxicam is not recommended in these patients with advanced renal disease. If 
meloxicam therapy must be initiated, close monitoring of the patient's renal 
function is advisable.</paragraph>
                     </text>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="f40f65b5-59f9-4ac5-adf6-d2fcca1345c8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Anaphylactoid Reactions</title>
                     <text>
                        <paragraph>As with other NSAIDS, anaphylactoid reactions have occurred in patients without 
known prior exposure to meloxicam. Meloxicam should not be given to patients 
with the aspirin triad. This symptom complex typically occurs in asthmatic 
patients who experience rhinitis with or without nasal polyps, or who exhibit 
severe, potentially fatal bronchospasm after taking aspirin or other NSAIDs (see 
<content styleCode="bold">
                              <linkHtml href="#ID25">CONTRAINDICATIONS </linkHtml>
                           </content>and <content styleCode="bold">
                              <linkHtml href="#ID47">PRECAUTIONS</linkHtml>
                           </content>, <content styleCode="bold">
                              <linkHtml href="#ID56">Pre-existing Asthma</linkHtml>
                           </content>). Emergency help should be sought in 
cases where an anaphylactoid reaction occurs.</paragraph>
                     </text>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="bff5de81-2c35-4702-b85b-66e677fef2ec"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Skin Reactions</title>
                     <text>
                        <paragraph>NSAIDs, including meloxicam can cause serious skin adverse events such as 
exfoliative dermatitis, Stevens - Johnson syndrome (SJS), and toxic epidermal 
necrolysis (TEN), which can be fatal. These serious events may occur without 
warning. Patients should be informed about the signs and symptoms of serious 
skin manifestations and use of the drug should be discontinued at the first 
appearance of skin rash or any other sign of hypersensitivity.</paragraph>
                     </text>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="7352f969-67a8-43e7-b6f4-e4b9be83f6f7"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>Pregnancy</title>
                     <text>
                        <paragraph>In late pregnancy, as with other NSAIDs, meloxicam should be avoided because it 
may cause premature closure of the ductus arteriosus.</paragraph>
                     </text>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="757da267-32ce-46c3-bea2-7c4ce6a211fb"/>
               <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
               <title>PRECAUTIONS</title>
               <text>
                  <paragraph>Enter section text here</paragraph>
               </text>
               <effectiveTime value="20100722"/>
               <component>
                  <section>
                     <id root="36aa7dfe-5c13-4af2-a37d-70514a893f4e"/>
                     <code code="34072-9" codeSystem="2.16.840.1.113883.6.1" displayName="GENERAL PRECAUTIONS SECTION"/>
                     <title>General</title>
                     <text>
                        <paragraph>
                           <linkHtml href=""/>Meloxicam cannot be expected to substitute for 
corticosteroids or to treat corticosteroid insufficiency. Abrupt discontinuation 
of corticosteroids may lead to disease exacerbation. Patients on prolonged 
corticosteroid therapy should have their therapy tapered slowly if a decision is 
made to discontinue corticosteroids.</paragraph>
                        <paragraph>The pharmacological activity of meloxicam in reducing fever and inflammation 
may diminish the utility of these diagnostic signs in detecting complications of 
presumed noninfectious, painful conditions.</paragraph>
                     </text>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="7eb664e9-21a5-405f-8717-9d2e4c2917b6"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Hepatic Effects</title>
                     <text>
                        <paragraph>
                           <linkHtml href=""/>Borderline elevations of one or more liver tests may occur 
in up to 15% of patients taking NSAIDs including meloxicam. These laboratory 
abnormalities may progress, may remain unchanged, or may be transient with 
continuing therapy. Notable elevations of ALT or AST (approximately three or 
more times the upper limit of normal) have been reported in approximately 1% of 
patients in clinical trials with NSAIDs. In addition, rare cases of severe 
hepatic reactions, including jaundice and fatal fulminant hepatitis, liver 
necrosis and hepatic failure, some of them with fatal outcomes have been 
reported.</paragraph>
                        <paragraph>A patient with symptoms and/or signs suggesting liver dysfunction, or in whom 
an abnormal liver test has occurred, should be evaluated for evidence of the 
development of a more severe hepatic reaction while on therapy with meloxicam. 
If clinical signs and symptoms consistent with liver disease develop, or if 
systemic manifestations occur (e.g., eosinophilia, rash, etc.), meloxicam should 
be discontinued.</paragraph>
                     </text>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="ead12c17-d117-4e7f-83cc-fff491bdfd22"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Renal Effects</title>
                     <text>
                        <paragraph>
                           <linkHtml href=""/>Caution should be used when initiating treatment with 
meloxicam in patients with considerable dehydration. It is advisable to 
rehydrate patients first and then start therapy with meloxicam. Caution is also 
recommended in patients with pre-existing kidney disease (see <content styleCode="bold">
                              <linkHtml href="#ID27">WARNINGS</linkHtml>
                           </content>, <content styleCode="bold">
                              <linkHtml href="#ID37">Renal Effects </linkHtml>
                           </content>and <content styleCode="bold">
                              <linkHtml href="#ID39">Advanced Renal Disease</linkHtml>
                           </content>).</paragraph>
                        <paragraph>The extent to which metabolites may accumulate in patients with renal failure 
has not been studied with meloxicam. Because some meloxicam metabolites are 
excreted by the kidney, patients with significantly impaired renal function 
should be more closely monitored.</paragraph>
                     </text>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="52b076f1-0bb1-4f2d-94c8-7bc5d702a6be"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Hematological Effects</title>
                     <text>
                        <paragraph>
                           <linkHtml href=""/>Anemia is sometimes seen in patients receiving NSAIDs, 
including meloxicam. This may be due to fluid retention, occult or gross GI 
blood loss, or an incompletely described effect upon erythropoiesis. Patients on 
long-term treatment with NSAIDs, including meloxicam, should have their 
hemoglobin or hematocrit checked if they exhibit any signs or symptoms of 
anemia.</paragraph>
                        <paragraph>Drugs which inhibit the biosynthesis of prostaglandins may interfere to some 
extent with platelet function and vascular responses to bleeding.</paragraph>
                        <paragraph>NSAIDs inhibit platelet aggregation and have been shown to prolong bleeding 
time in some patients. Unlike aspirin their effect on platelet function is 
quantitatively less, of shorter duration, and reversible. Patients receiving 
meloxicam who may be adversely affected by alterations in platelet function, 
such as those with coagulation disorders or patients receiving anticoagulants 
should be carefully monitored. </paragraph>
                     </text>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="bac28979-21e5-4f53-9420-145d60f15e18"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Pre-existing Asthma</title>
                     <text>
                        <paragraph>Patients with asthma may have aspirin-sensitive asthma. The use of aspirin in 
patients with aspirin-sensitive asthma has been associated with severe 
bronchospasm which can be fatal. Since cross reactivity, including bronchospasm, 
between aspirin and other NSAIDs has been reported in such aspirin-sensitive 
patients, meloxicam should not be administered to patients with this form of 
aspirin sensitivity and should be used with caution in patients with 
pre-existing asthma.</paragraph>
                     </text>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="26b78290-428e-496a-8213-228f862a0de1"/>
                     <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
                     <title>Information for Patients</title>
                     <text>
                        <paragraph>
                           <linkHtml href=""/>
                           <content styleCode="bold">Patients should be informed of the 
following information before initiating therapy with an NSAID and periodically 
during the course of ongoing therapy. Patients should also be encouraged to read 
the NSAID Medication Guide that accompanies each prescription dispensed.</content>
                        </paragraph>
                        <list listType="ordered" ID="i1e719b3c-c477-4ac1-87bf-fbc805065c8d">
                           <item>Meloxicam, like other NSAIDs, may cause serious CV side effects, such as MI 
or stroke, which may result in hospitalization and even death. Although serious 
CV events can occur without warning symptoms, patients should be alert for the 
signs and symptoms of chest pain, shortness of breath, weakness, slurring of 
speech, and should ask for medical advice when observing any indicative sign or 
symptoms. Patients should be apprised of the importance of this follow-up (see 
<content styleCode="bold">
                                 <linkHtml href="#ID27">WARNINGS</linkHtml>
                              </content>, <content styleCode="bold">
                                 <linkHtml href="#ID28">Cardiovascular Effects</linkHtml>
                              </content>). </item>
                           <item>Meloxicam, like other NSAIDs, can cause GI discomfort and, rarely, serious 
GI side effects, such as ulcers and bleeding, which may result in 
hospitalization and even death. Although serious GI tract ulcerations and 
bleeding can occur without warning symptoms, patients should be alert for the 
signs and symptoms of ulcerations and bleeding, and should ask for medical 
advice when observing any indicative sign or symptoms including epigastric pain, 
dyspepsia, melena, and hematemesis. Patients should be apprised of the 
importance of this follow-up (see <content styleCode="bold">
                                 <linkHtml href="#ID27">WARNINGS</linkHtml>
                              </content>, <content styleCode="bold">
                                 <linkHtml href="#ID35">Gastrointestinal (GI) Effects - Risk of GI Ulceration, Bleeding, 
and Perforation</linkHtml>
                              </content>).</item>
                           <item>Meloxicam, like other NSAIDs, can cause serious skin side effects such as 
exfoliative dermatitis, SJS, and TEN, which may result in hospitalizations and 
even death. Although serious skin reactions may occur without warning, patients 
should be alert for the signs and symptoms of skin rash and blisters, fever, or 
other signs of hypersensitivity such as itching, and should ask for medical 
advice when observing any indicative signs or symptoms. Patients should be 
advised to stop the drug immediately if they develop any type of rash and 
contact their physicians as soon as possible.</item>
                           <item>Patients should promptly report signs or symptoms of unexplained weight gain 
or edema to their physicians.</item>
                           <item>Patients should be informed of the warning signs and symptoms of 
hepatotoxicity (e.g., nausea, fatigue, lethargy, pruritus, jaundice, right upper 
quadrant tenderness, and "flu-like" symptoms). If these occur, patients should 
be instructed to stop therapy and seek immediate medical therapy.</item>
                           <item>Patients should be informed of the signs of an anaphylactoid reaction (e.g., 
difficulty breathing, swelling of the face or throat). If these occur, patients 
should be instructed to seek immediate emergency help (see <content styleCode="bold">
                                 <linkHtml href="#ID27">WARNINGS</linkHtml>
                              </content>).</item>
                           <item>In late pregnancy, as with other NSAIDs, meloxicam should be avoided because 
it will cause premature closure of the ductus arteriosus.</item>
                        </list>
                     </text>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="520b57ae-64fe-4fb4-9093-3049612b1235"/>
                     <code code="34075-2" codeSystem="2.16.840.1.113883.6.1" displayName="LABORATORY TESTS SECTION"/>
                     <title>Laboratory Tests</title>
                     <text>
                        <paragraph>Because serious GI tract ulcerations and bleeding can occur without warning 
symptoms, physicians should monitor for signs or symptoms of GI bleeding. 
Patients on long-term treatment with NSAIDs should have their CBC and a 
chemistry profile checked periodically. If clinical signs and symptoms 
consistent with liver or renal disease develop, systemic manifestations occur 
(e.g., eosinophilia, rash, etc.) or if abnormal liver tests persist or worsen, 
meloxicam should be discontinued.</paragraph>
                     </text>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="57fda5de-e944-422b-9f82-4f42dbc167ea"/>
                     <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
                     <title>Drug Interactions</title>
                     <text>
                        <linkHtml href=""/>ACE-inhibitors<paragraph>
                           <linkHtml href=""/>Reports suggest that NSAIDs may diminish the 
antihypertensive effect of ACE-inhibitors. This interaction should be given 
consideration in patients taking NSAIDs concomitantly with ACE inhibitors.</paragraph>
                        <linkHtml href=""/>
                        <linkHtml href=""/>
                        <linkHtml href=""/>Aspirin<paragraph>
                           <linkHtml href=""/>When meloxicam is administered with aspirin (1000 g TID) to 
healthy volunteers, it tended to increase the AUC (10%) and C<sub>max</sub> (24%) of meloxicam. The clinical significance of this 
interaction is not known; however, as with other NSAIDs concomitant 
administration of meloxicam and aspirin is not generally recommended because of 
the potential for increased adverse effects.</paragraph>
                        <paragraph>Concomitant administration of low-dose aspirin with meloxicam may result in 
an increased rate of GI ulceration or other complications, compared to use of 
meloxicam alone. Meloxicam is not a substitute for aspirin for cardiovascular 
prophylaxis.</paragraph>
                        <linkHtml href=""/>
                        <linkHtml href=""/>
                        <linkHtml href=""/>Cholestyramine<paragraph>
                           <linkHtml href=""/>Pretreatment for four days with cholestyramine significantly 
increased the clearance of meloxicam by 50%. This resulted in a decrease in 
t<sub>1/2</sub>, from 19.2 hours to 12.5 hours, and a 35% reduction 
in AUC. This suggests the existence of a recirculation pathway for meloxicam in 
the gastrointestinal tract. The clinical relevance of this interaction has not 
been established.</paragraph>
                        <linkHtml href=""/>
                        <linkHtml href=""/>
                        <linkHtml href=""/>Cimetidine<paragraph>
                           <linkHtml href=""/>Concomitant administration of 200 mg cimetidine QID did not 
alter the single-dose pharmacokinetics of 30 mg meloxicam.</paragraph>
                        <linkHtml href=""/>
                        <linkHtml href=""/>
                        <linkHtml href=""/>Digoxin<paragraph>
                           <linkHtml href=""/>Meloxicam 15 mg once daily for 7 days did not alter the 
plasma concentration profile of digoxin after β-acetyldigoxin administration for 
7 days at clinical doses. <content styleCode="italics">In vitro </content>testing found no 
protein binding drug interaction between digoxin and meloxicam.</paragraph>
                        <paragraph>
                           <content>Furosemide</content>
                        </paragraph>
                        <paragraph>Clinical studies, as well as post-marketing observations, have shown that 
NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some 
patients. This response has been attributed to inhibition of renal prostaglandin 
synthesis. Studies with furosemide agents and meloxicam have not demonstrated a 
reduction in natriuretic effect. Furosemide single and multiple dose 
pharmacodynamics and pharmacokinetics are not affected by multiple doses of 
meloxicam. Nevertheless, during concomitant therapy with meloxicam, patients 
should be observed closely for signs of renal failure (see <content styleCode="bold">
                              <linkHtml href="#ID27">WARNINGS</linkHtml>
                           </content>, <content styleCode="bold">
                              <linkHtml href="#ID37">Renal 
Effects</linkHtml>
                           </content>), as well as to assure diuretic efficacy.</paragraph>
                        <linkHtml href=""/>
                        <linkHtml href=""/>
                        <linkHtml href=""/>Lithium<paragraph>
                           <linkHtml href=""/>In a study conducted in healthy subjects, mean pre-dose 
lithium concentration and AUC were increased by 21% in subjects receiving 
lithium doses ranging from 804 to 1072 mg BID with meloxicam 15 mg QD as 
compared to subjects receiving lithium alone. These effects have been attributed 
to inhibition of renal prostaglandin synthesis by meloxicam. Patients on lithium 
treatment should be closely monitored for signs of lithium toxicity when 
meloxicam is introduced, adjusted, or withdrawn.</paragraph>
                        <linkHtml href=""/>
                        <linkHtml href=""/>
                        <linkHtml href=""/>Methotrexate<paragraph>
                           <linkHtml href=""/>NSAIDs have been reported to competitively inhibit 
methotrexate accumulation in rabbit kidney slices. This may indicate that they 
could enhance the toxicity of methotrexate. Caution should be used when NSAIDs 
are administered concomitantly with methotrexate.</paragraph>
                        <paragraph>A study in 13 rheumatoid arthritis (RA) patients evaluated the effects of 
multiple doses of meloxicam on the pharmacokinetics of methotrexate taken once 
weekly. Meloxicam did not have a significant effect on the pharmacokinetics of 
single doses of methotrexate.<content styleCode="italics">In vitro</content>, methotrexate 
did not displace meloxicam from its human serum binding sites.</paragraph>
                        <linkHtml href=""/>
                        <linkHtml href=""/>
                        <linkHtml href=""/>Warfarin<paragraph>
                           <linkHtml href=""/>The effects of warfarin and NSAIDs on GI bleeding are 
synergistic, such that users of both drugs together have a risk of serious GI 
bleeding higher than users of either drug alone.</paragraph>
                        <paragraph>Anticoagulant activity should be monitored, particularly in the first few 
days after initiating or cha nging meloxicam therapy in patients receiving 
warfarin or similar agents, since these patients are at an increased risk of 
bleeding. The effect of meloxicam on the anticoagulant effect of warfarin was 
studied in a group of healthy subjects receiving daily doses of warfarin that 
produced an INR (International Normalized Ratio) between 1.2 and 1.8. In these 
subjects, meloxicam did not alter warfarin pharmacokinetics and the average 
anticoagulant effect of warfarin as determined by prothrombin time. However, one 
subject showed an increase in INR from 1.5 to 2.1. Caution should be used when 
administering meloxicam with warfarin since patients on warfarin may experience 
changes in INR and an increased risk of bleeding complications when a new 
medication is introduced.</paragraph>
                     </text>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="b2fb416d-e5aa-480c-ae3a-48a939dce84f"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>
                           <linkHtml href=""/>No carcinogenic effect of meloxicam was observed in rats 
given oral doses up to 0.8 mg/kg/day (approximately 0.4-fold the human dose at 
15 mg/day for a 50 kg adult based on body surface area conversion) for 104 weeks 
or in mice given oral doses up to 8.0 mg/kg/day (approximately 2.2-fold the 
human dose, as noted above) for 99 weeks.</paragraph>
                        <paragraph>Meloxicam was not mutagenic in an Ames assay, or clastogenic in a chromosome 
aberration assay with human lymphocytes and an <content styleCode="italics">in vivo 
</content>micronucleus test in mouse bone marrow. </paragraph>
                        <paragraph>Meloxicam did not impair male and female fertility in rats at oral doses up 
to 9 and 5 mg/kg/day, respectively (4.9-fold and 2.5-fold the human dose, as 
noted above). However, an increased incidence of embryolethality at oral doses 
≥1 mg/kg/day (0.5-fold the human dose, as noted above) was observed in rats when 
dams were given meloxicam 2 weeks prior to mating and during early embryonic 
development. </paragraph>
                     </text>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="764aaf12-8642-48c0-9281-31648af27fb2"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>Pregnancy</title>
                     <text>
                        <paragraph>
                           <linkHtml href=""/>
                           <content styleCode="bold">Teratogenic Effects: </content>
                           <content styleCode="italics">Pregnancy Category C.</content>
                        </paragraph>
                        <paragraph>Meloxicam caused an increased incidence of septal defect of the heart, a rare 
event, at an oral dose of 60 mg/kg/day (64.5-fold the human dose at 15 mg/day 
for a 50 kg adult based on body surface area conversion) and embryolethality at 
oral doses ≥5 mg/kg/day (5.4-fold the human dose, as noted above) when rabbits 
were treated throughout organogenesis. Meloxicam was not teratogenic in rats up 
to an oral dose of 4 mg/kg/day (approximately 2.2-fold the human dose, as noted 
above) throughout organogenesis. An increased incidence of stillbirths was 
observed when rats were given oral doses ≥1 mg/kg/day throughout organogenesis. 
Meloxicam crosses the placental barrier. There are no adequate and 
well-controlled studies in pregnant women. Meloxicam should be used during 
pregnancy only if the potential benefit justifies the potential risk to the 
fetus.</paragraph>
                        <linkHtml href=""/>
                        <linkHtml href=""/>
                        <paragraph>
                           <linkHtml href=""/>
                           <content styleCode="italics">Nonteratogenic Effects</content>
                        </paragraph>
                        <paragraph>Because of the known effects of nonsteroidal antiinflammatory drugs on the 
fetal cardiovascular system (closure of ductus arteriosus), use during pregnancy 
(particularly late pregnancy) should be avoided.</paragraph>
                        <paragraph>Meloxicam caused a reduction in birth index, live births, and neonatal 
survival at oral doses ≥0.125 mg/kg/day (approximately 0.07-fold the human dose 
at 15 mg/day for a 50 kg adult based on body surface area conversion) when rats 
were treated during the late gestation and lactation period. No studies have 
been conducted to evaluate the effect of meloxicam on the closure of the ductus 
arteriosus in humans; use of meloxicam during the third trimester of pregnancy 
should be avoided.</paragraph>
                     </text>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="80f3e33b-2e57-4c59-b520-8d0d4102c695"/>
                     <code code="34079-4" codeSystem="2.16.840.1.113883.6.1" displayName="LABOR &amp; DELIVERY SECTION"/>
                     <title>Labor and Delivery</title>
                     <text>
                        <paragraph>
                           <linkHtml href=""/>Studies in rats with meloxicam, as with other drugs known to 
inhibit prostaglandin synthesis, showed an increased incidence of stillbirths, 
prolonged delivery, and delayed parturition at oral dosages ≥1 mg/kg/day 
(approximately 0.5-fold the human dose at 15 mg/day for a 50 kg adult based on 
body surface area conversion), and decreased pup survival at an oral dose of 4 
mg/kg/day (approximately 2.1-fold the human dose, as noted above) throughout 
organogenesis. Similar findings were observed in rats receiving oral dosages 
≥0.125 mg/kg/day (approximately 0.07-fold the human dose, as noted above) during 
late gestation and the lactation period.</paragraph>
                        <paragraph>The effects of meloxicam on labor and delivery in pregnant women are unknown.</paragraph>
                     </text>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="41c1bae6-d570-406b-97da-163f7de843f6"/>
                     <code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION"/>
                     <title>Nursing Mothers</title>
                     <text>
                        <paragraph>It is not known whether this drug is excreted in human milk however, meloxicam 
was excreted in the milk of lactating rats at concentrations higher than those 
in plasma. Because many drugs are excreted in human milk and because of the 
potential for serious adverse reactions in nursing infants from meloxicam, a 
decision should be made whether to discontinue nursing or to discontinue the 
drug, taking into account the importance of the drug to the mother.</paragraph>
                     </text>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="352496e9-62da-4391-8f77-abca0a0b92fb"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>Pediatric Use</title>
                     <text>
                        <paragraph>Use of this drug for a pediatric indication is protected by marketing 
exclusivity.</paragraph>
                     </text>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="299b481f-2ef1-4bd7-b3de-41e81d1aea74"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>Geriatric Use</title>
                     <text>
                        <paragraph>As with any NSAID, caution should be exercised in treating the elderly (65 years 
and older).</paragraph>
                     </text>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="df3fb643-123c-4e60-b73e-76676ebc0a08"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>ADVERSE REACTIONS</title>
               <text>
                  <paragraph>Enter section text here</paragraph>
               </text>
               <effectiveTime value="20100722"/>
               <component>
                  <section>
                     <id root="6dd4cc57-988b-4468-8c63-27bc3b76ab88"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Adults</title>
                     <text>
                        <paragraph>
                           <linkHtml href=""/>
                           <content>Osteoarthritis and Rheumatoid 
Arthritis</content>
                        </paragraph>
                        <paragraph>The meloxicam Phase 2/3 clinical trial database includes 10,122 OA patients 
and 1012 RA patients treated with meloxicam 7.5 mg/day and 3,505 OA patients and 
1351 RA patients treated with meloxicam 15 mg/day. Meloxicam at these doses was 
administered to 661 patients for at least 6 months and to 312 patients for at 
least one year. Approximately 10,500 of these patients were treated in ten 
placebo and/or active-controlled osteoarthritis trials and 2363 of this patients 
were treated in ten placebo and/or active controlled rheumatoid arthritis 
trials. Gastrointestinal (GI) adverse events were the most frequently reported 
adverse events in all treatment groups across meloxicam trials. </paragraph>
                        <paragraph>A 12-week multicenter, double-blind, randomized trial was conducted in 
patients with osteoarthritis of the knee or hip to compare the efficacy and 
safety of meloxicam with placebo and with an active control. Two 12-week 
multicenter, double-blind, randomized trials were conducted in patients with 
rheumatoid arthritis to compare the efficacy and safety of meloxicam with 
placebo. </paragraph>
                        <paragraph>Table 2a depicts adverse events that occurred in ≥ 2% of the meloxicam 
treatment groups in a 12-week placebo and active-controlled osteoarthritis 
trial.</paragraph>
                        <paragraph>Table 2b depicts adverse events that occurred in ≥2% of the meloxicam 
treatment groups in two 12-week placebo controlled rheumatoid arthritis trials.</paragraph>
                        <table width="100%" ID="i1af256f1-dee2-4ece-8329-0559c1fd8706">
                           <caption>Table 2a Adverse Events (%) Occurring in ≥ 2% of Meloxicam Patients in a 12-Week Osteoarthritis Placebo and Active-Controlled Trial</caption>
                           <tbody>
                              <tr>
                                 <td>
                                    <br/>
                                 </td>
                                 <td>
                                    <content styleCode="bold">Placebo<br/>
                                       <br/>
                                    </content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">MELOXICAM<br/>7.5 mg daily<br/>
                                    </content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">MELOXICAM<br/>15 mg daily<br/>
                                    </content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">Diclofenac<br/>100 mg daily<br/>
                                    </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>
                                    <content styleCode="bold">No. of Patients</content>
                                    <br/>
                                 </td>
                                 <td>
                                    <content styleCode="bold">157</content>
                                    <br/>
                                 </td>
                                 <td>
                                    <content styleCode="bold">154</content>
                                    <br/>
                                 </td>
                                 <td>
                                    <content styleCode="bold">156</content>
                                    <br/>
                                 </td>
                                 <td>
                                    <content styleCode="bold">153</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td>
                                    <content styleCode="bold">Gastrointestinal</content>
                                    <br/>     Abdominal Pain<br/>     Diarrhea<br/>     Dyspepsia<br/>     Flatulence<br/>     Nausea<br/>
                                 </td>
                                 <td>17.2<br/>2.5<br/>3.8<br/>4.5<br/>4.5<br/>3.2<br/>
                                 </td>
                                 <td>20.1<br/>1.9<br/>7.8<br/>4.5<br/>3.2<br/>3.9<br/>
                                 </td>
                                 <td>17.3<br/>2.6<br/>3.2<br/>4.5<br/>3.2<br/>3.8<br/>
                                 </td>
                                 <td>28.1<br/>1.3<br/>9.2<br/>6.5<br/>3.9<br/>7.2<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td>
                                    <content styleCode="bold">Body as a Whole<br/>     </content>Accident Household<br/>     Edema<sup>1</sup>
                                    <br/>     Fall<br/>     Influenza-Like Symptoms<br/>
                                 </td>
                                 <td>
                                    <br/>1.9<br/>2.5<br/>0.6<br/>5.1<br/>
                                 </td>
                                 <td>
                                    <br/>4.5<br/>1.9<br/>2.6<br/>4.5<br/>
                                 </td>
                                 <td>
                                    <br/>3.2<br/>4.5<br/>0.0<br/>5.8<br/>
                                 </td>
                                 <td>
                                    <br/>2.6<br/>3.3<br/>1.3<br/>2.6<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td>
                                    <content styleCode="bold">Central and Peripheral Nervous System<br/>     </content>Dizziness<br/>     Headache<br/>
                                 </td>
                                 <td>
                                    <br/>3.2<br/>10.2<br/>
                                 </td>
                                 <td>
                                    <br/>2.6<br/>7.8<br/>
                                 </td>
                                 <td>
                                    <br/>3.8<br/>8.3<br/>
                                 </td>
                                 <td>
                                    <br/>2.0<br/>5.9<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td>
                                    <content styleCode="bold">Respiratory<br/>     </content>Pharyngitis<br/>     Upper Respiratory Tract Infection<br/>
                                 </td>
                                 <td>
                                    <br/>1.3<br/>1.9<br/>
                                 </td>
                                 <td>
                                    <br/>0.6<br/>3.2<br/>
                                 </td>
                                 <td>
                                    <br/>3.2<br/>1.9<br/>
                                 </td>
                                 <td>
                                    <br/>1.3<br/>3.3<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td>
                                    <content styleCode="bold">Skin<br/>     </content>Rash<sup>2</sup>
                                 </td>
                                 <td>
                                    <br/>2.5<br/>
                                 </td>
                                 <td>
                                    <br/>2.6<br/>
                                 </td>
                                 <td>
                                    <br/>0.6<br/>
                                 </td>
                                 <td>
                                    <br/>2.0<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <sup>1</sup>  WHO preferred terms edema, edema dependent, edema peripheral and edema legs combined 
<br/>
                        <sup>2</sup>  WHO preferred terms rash, rash erythematous and rash maculo-papular combined<br/>
                        <br/>
                        <br/>
                        <table width="100%" ID="i1a3e2fb0-4ed1-4605-891e-5397a2382b4d">
                           <caption>Table 2b Adverse Events (%) Occurring in ≥ 2% of Meloxicam
Patients in two 12-Week Rheumatoid Arthritis Placebo Controlled Trials</caption>
                           <tbody>
                              <tr>
                                 <td>
                                    <br/>
                                 </td>
                                 <td>
                                    <content styleCode="bold">Placebo<br/>
                                       <br/>
                                    </content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">MELOXICAM<br/>
7.5 mg daily<br/>
                                    </content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">MELOXICAM<br/>
15 mg daily<br/>
                                    </content>
                                 </td>
                                 <td>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td>
                                    <content styleCode="bold">No. of Patients</content>
                                    <br/>
                                 </td>
                                 <td>
                                    <content styleCode="bold">469</content>
                                    <br/>
                                 </td>
                                 <td>
                                    <content styleCode="bold">481</content>
                                    <br/>
                                 </td>
                                 <td>
                                    <content styleCode="bold">477</content>
                                    <br/>
                                 </td>
                                 <td>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td>
                                    <content styleCode="bold">Gastrointestinal disorders</content>
                                    <br/>
     Abdominal Pain NOS<sup>2</sup>
                                    <br/>
     Diarrhea NOS<sup>2</sup>
                                    <br/>
     Dyspepsia signs and symptoms<sup>1</sup>
                                    <br/>
     Nausea<sup>2</sup>
                                    <br/>
                                 </td>
                                 <td>14.1<br/>0.6<br/>5.1<br/>3.8<br/>2.6<br/>
                                 </td>
                                 <td>18.9<br/>2.9<br/>4.8<br/>5.8<br/>3.3<br/>
                                 </td>
                                 <td>16.8<br/>2.3<br/>3.4<br/>4.0<br/>3.8<br/>
                                 </td>
                                 <td>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td>
                                    <content styleCode="bold">General disorders and administration site conditions<br/>     </content>Influenza like illness<sup>2</sup>
                                    <content styleCode="bold">
                                       <sup/>
                                    </content>
                                    <sup/>
                                    <br/>
                                 </td>
                                 <td>
                                    <br/>2.1<br/>
                                 </td>
                                 <td>
                                    <br/>2.9<br/>
                                 </td>
                                 <td>
                                    <br/>2.3<br/>
                                 </td>
                                 <td>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td>
                                    <content styleCode="bold">Infection and Infestations<br/>     </content>Upper respiratory tract infections-<br/>     Pathogen class unspecified<sup>1</sup>
                                    <br/>
                                 </td>
                                 <td>
                                    <br/>4.1<br/>
                                    <br/>
                                 </td>
                                 <td>
                                    <br/>7.0<br/>
                                    <br/>
                                 </td>
                                 <td>
                                    <br/>6.5<br/>
                                    <br/>
                                 </td>
                                 <td>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td>
                                    <content styleCode="bold">Musculoskeletal and connective tissue disorders<br/>     </content>Joint related signs and symptoms<sup>1</sup>
                                    <br/>     Musculoskeletal and connective tissue<br/>     signs and symptoms NEC<sup>1</sup>
                                    <br/>
                                 </td>
                                 <td>
                                    <br/>1.9<br/>3.8<br/>
                                    <br/>
                                 </td>
                                 <td>
                                    <br/>1.5<br/>1.7<br/>
                                    <br/>
                                 </td>
                                 <td>
                                    <br/>2.3<br/>2.9<br/>
                                    <br/>
                                 </td>
                                 <td>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td>
                                    <content styleCode="bold">Nervous system disorders<br/>
     </content>Headaches NOS<sup>2</sup>
                                    <br/>     Dizziness (excl vertigo)<sup>2</sup>
                                    <br/>
                                    <content styleCode="bold">Skin and subcutaneous tissue disorders<br/>     </content>Rash NOS<sup>2</sup>
                                    <br/>
                                 </td>
                                 <td>
                                    <br/>6.4<br/>3.0<br/>
                                    <br/>1.7<br/>
                                 </td>
                                 <td>
                                    <br/>6.4<br/>2.3<br/>
                                    <br/>1.0<br/>
                                 </td>
                                 <td>
                                    <br/>5.5<br/>0.4<br/>
                                    <br/>2.1<br/>
                                 </td>
                                 <td>
                                    <br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <sup>1</sup>  MedDRA high level term (preferred terms): dyspeptic signs and symptoms 
(dyspepsia, dyspepsia aggravated, eructation, gastrointestinal irritation), 
upper respiratory tract infections-pathogen unspecified (laryngitis NOS, 
pharyngitis NOS, sinusitis NOS), joint related signs and symptoms (arthralgia, 
arthralgia aggravated, joint crepitation, joint effusion, joint swelling), and 
musculoskeletal and connective tissue signs and symptoms NEC (back pain, back 
pain aggravated, muscle spasms, musculoskeletal pain) <br/>
                        <sup>2</sup>  MedDRA preferred term: diarrhea NOS, nausea, abdominal pain NOS, influenza like 
illness, headaches NOS, dizziness (excl vertigo), and rash NOS <br/>
                        <br/>
                     </text>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="78cae48f-4414-4a24-9325-0f38836c2b11"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>The adverse events that occurred with meloxicam in ≥ 2% of patients treated 
short-term (4-6 weeks) and long-term (6 months) in active-controlled 
osteoarthritis trials are presented in Table 3.</paragraph>
                        <table width="100%" ID="i3be740d9-1637-4afa-8bf5-6d3265c1b038">
                           <caption>Table 3 Adverse Events (%) Occurring in ≥ 2% of Meloxicam Patients in 4 to 6 Weeks and 6 Month Active-Controlled Osteoarthritis Trials</caption>
                           <thead>
                              <tr>
                                 <th>
                                    <br/>
                                 </th>
                                 <th> 4-6 Weeks Controlled</th>
                                 <th>Trials<br/>
                                 </th>
                                 <th> 6 Month<br/>
                                 </th>
                                 <th> Controlled Trials<br/>
                                 </th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr>
                                 <td>
                                    <br/>
                                 </td>
                                 <td>
                                    <content styleCode="bold">MELOXICAM<br/>7.5 mg daily</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">MELOXICAM       <br/>15 mg daily</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">MELOXICAM<br/>7.5 mg daily</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">MELOXICAM<br/>15 mg daily</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>
                                    <content styleCode="bold">No. of Patients</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">8955</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">256</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">169</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">306</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>
                                    <content styleCode="bold">Gastrointestinal<br/>     </content>Abdominal Pain<br/>     Constipation<br/>     Diarrhea<br/>     Dyspepsia<br/>     Flatulence<br/>     Nausea<br/>     Vomiting<br/>
                                 </td>
                                 <td>11.8<br/>2.7<br/>0.8<br/>1.9<br/>3.8<br/>0.5<br/>2.4<br/>0.6<br/>
                                 </td>
                                 <td>18.0<br/>2.3<br/>1.2<br/>2.7<br/>7.4<br/>0.4<br/>4.7<br/>0.8<br/>
                                 </td>
                                 <td>26.6<br/>4.7<br/>1.8<br/>5.9<br/>8.9<br/>3.0<br/>4.7<br/>1.8<br/>
                                 </td>
                                 <td>24.2<br/>2.9<br/>2.6<br/>2.6<br/>9.5<br/>2.6<br/>7.2<br/>2.6<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td>
                                    <content styleCode="bold">Body as a Whole<br/>     </content>Accident Household<br/>     Edema<sup>1</sup>
                                    <br/>     Pain<br/>
                                 </td>
                                 <td>
                                    <br/>0.0<br/>0.6<br/>0.90<br/>
                                 </td>
                                 <td>
                                    <br/>0.0<br/>2.0<br/>2.0<br/>
                                 </td>
                                 <td>
                                    <br/>0.6<br/>2.4<br/>3.6<br/>
                                 </td>
                                 <td>
                                    <br/>2.9<br/>1.6<br/>5.2<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td>
                                    <content styleCode="bold">Central and Peripheral Nervous System<br/>     </content>Dizziness<br/>     Headache<br/>
                                 </td>
                                 <td>
                                    <br/>1.1<br/>2.4<br/>
                                 </td>
                                 <td>
                                    <br/>1.6<br/>2.7<br/>
                                 </td>
                                 <td>
                                    <br/>2.4<br/>3.6<br/>
                                 </td>
                                 <td>
                                    <br/>2.6<br/>2.6<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td>
                                    <content styleCode="bold">Hematologic<br/>     </content>Anemia</td>
                                 <td>
                                    <br/>0.1<br/>
                                 </td>
                                 <td>
                                    <br/>0.0<br/>
                                 </td>
                                 <td>
                                    <br/>4.1<br/>
                                 </td>
                                 <td>
                                    <br/>2.9<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td>
                                    <content styleCode="bold">Musculoskeletal<br/>     </content>Arthralgia<br/>     Back Pain<br/>
                                 </td>
                                 <td>
                                    <br/>0.5<br/>0.5<br/>
                                 </td>
                                 <td>
                                    <br/>0.0<br/>0.4<br/>
                                 </td>
                                 <td>
                                    <br/>5.3<br/>3.0<br/>
                                 </td>
                                 <td>
                                    <br/>1.3<br/>0.7<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td>
                                    <content styleCode="bold">Psychiatric<br/>     </content>Insomnia</td>
                                 <td>
                                    <br/>0.4<br/>
                                 </td>
                                 <td>
                                    <br/>0.0<br/>
                                 </td>
                                 <td>
                                    <br/>3.6<br/>
                                 </td>
                                 <td>
                                    <br/>1.6<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td>
                                    <content styleCode="bold">Respiratory<br/>     </content>Coughing<br/>     Upper Respiratory Tract Infection<br/>
                                 </td>
                                 <td>
                                    <br/>0.2<br/>0.2<br/>
                                 </td>
                                 <td>
                                    <br/>0.8<br/>0.0<br/>
                                 </td>
                                 <td>
                                    <br/>2.4<br/>8.3<br/>
                                 </td>
                                 <td>
                                    <br/>1.0<br/>7.5<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td>
                                    <content styleCode="bold">Skin<br/>     </content>Pruritus<br/>     Rash<sup>2</sup>
                                    <br/>
                                 </td>
                                 <td>
                                    <br/>0.4<br/>0.3<br/>
                                 </td>
                                 <td>
                                    <br/>1.2<br/>1.2<br/>
                                 </td>
                                 <td>
                                    <br/>2.4<br/>3.0<br/>
                                 </td>
                                 <td>
                                    <br/>0.0<br/>1.3<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td>
                                    <content styleCode="bold">Urinary<br/>     </content>Micturition Frequency<br/>     Urinary Tract Infection<br/>
                                 </td>
                                 <td>
                                    <br/>0.1<br/>0.3<br/>
                                 </td>
                                 <td>
                                    <br/>0.4<br/>0.4<br/>
                                 </td>
                                 <td>
                                    <br/>2.4<br/>4.7<br/>
                                 </td>
                                 <td>
                                    <br/>1.3<br/>6.9<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <sup>1</sup>  WHO preferred terms edema, edema dependent, edema peripheral and edema legs combined<br/>
                        <sup>2</sup>  WHO preferred terms rash, rash erythematous and rash maculo-papular combined<br/>
                        <br/>
                        <paragraph>
                           <linkHtml href=""/>Higher doses of meloxicam (22.5 mg and greater) have been 
associated with an increased risk of serious GI events; therefore the daily dose 
of meloxicam should not exceed 15 mg. </paragraph>
                        <paragraph>The following is a list of adverse drug reactions occurring in less than 2% of 
patients receiving meloxicam in clinical trials involving approximately 16,200 
patients. Adverse reactions reported only in worldwide post-marketing experience 
or the literature are shown in italics.</paragraph>
                        <linkHtml href=""/>
                        <table width="100%" ID="i7187d04a-36f0-4f25-86b2-6d2938b90260">
                           <col width="36%"/>
                           <col width="64%"/>
                           <thead>
                              <tr>
                                 <td>
                                    <paragraph>
                                       <content styleCode="bold">Body as a Whole  </content>
                                    </paragraph>
                                 </td>
                                 <td>allergic reaction, <content styleCode="italics">anaphylactoid reactions including shock,</content>
                                 </td>
                              </tr>
                           </thead>
                           <tbody>
                              <tr>
                                 <td>
                                    <paragraph>
                                       <content styleCode="bold"/>
                                    </paragraph>
                                    <br/>
                                 </td>
                                 <td>face edema, fatigue, fever, hot flushes, malaise, syncope, weight decrease, weight increase 
</td>
                              </tr>
                              <tr>
                                 <td>
                                    <paragraph>
                                       <content styleCode="bold">Cardiovascular  </content>
                                    </paragraph>
                                 </td>
                                 <td>angina pectoris, cardiac failure, hypertension, hypotension, 
</td>
                              </tr>
                              <tr>
                                 <td>
                                    <paragraph>
                                       <content styleCode="bold"/>
                                    </paragraph>
                                    <br/>
                                 </td>
                                 <td>myocardial infarction, vasculitis 
</td>
                              </tr>
                              <tr>
                                 <td>
                                    <paragraph>
                                       <content styleCode="bold">Central and Peripheral Nervous System  
</content>
                                    </paragraph>
                                 </td>
                                 <td>convulsions, paresthesia, tremor, vertigo </td>
                              </tr>
                              <tr>
                                 <td>
                                    <paragraph>
                                       <content styleCode="bold">Gastrointestinal  </content>
                                    </paragraph>
                                 </td>
                                 <td>colitis, dry mouth, duodenal ulcer, eructation, esophagitis, 
</td>
                              </tr>
                              <tr>
                                 <td>
                                    <paragraph>
                                       <content styleCode="bold"/>
                                    </paragraph>
                                    <br/>
                                 </td>
                                 <td>gastric ulcer, gastritis, gastroesophageal reflux, 
</td>
                              </tr>
                              <tr>
                                 <td>
                                    <paragraph>
                                       <content styleCode="bold"/>
                                    </paragraph>
                                    <br/>
                                 </td>
                                 <td>gastrointestinal hemorrhage, hematemesis, hemorrhagic 
</td>
                              </tr>
                              <tr>
                                 <td>
                                    <paragraph>
                                       <content styleCode="bold"/>
                                    </paragraph>
                                    <br/>
                                 </td>
                                 <td>duodenal ulcer, hemorrhagic gastric ulcer, intestinal 
</td>
                              </tr>
                              <tr>
                                 <td>
                                    <paragraph>
                                       <content styleCode="bold"/>
                                    </paragraph>
                                    <br/>
                                 </td>
                                 <td>perforation, melena, pancreatitis, </td>
                              </tr>
                              <tr>
                                 <td>
                                    <paragraph>
                                       <content styleCode="bold"/>
                                    </paragraph>
                                    <br/>
                                 </td>
                                 <td>perforated duodenal ulcer, perforated gastric ulcer,  
</td>
                              </tr>
                              <tr>
                                 <td>
                                    <paragraph>
                                       <content styleCode="bold"/>
                                    </paragraph>
                                    <br/>
                                 </td>
                                 <td>stomatitis ulcerative </td>
                              </tr>
                              <tr>
                                 <td>
                                    <paragraph>
                                       <content styleCode="bold">Heart Rate and Rhythm  </content>
                                    </paragraph>
                                 </td>
                                 <td>arrhythmia, palpitation, tachycardia </td>
                              </tr>
                              <tr>
                                 <td>
                                    <paragraph>
                                       <content styleCode="bold">Hematologic </content>
                                    </paragraph>
                                 </td>
                                 <td>
                                    <content styleCode="italics">agranulocytosis,</content> leukopenia, purpura, thrombocytopenia   
</td>
                              </tr>
                              <tr>
                                 <td>
                                    <paragraph>
                                       <content styleCode="bold">Liver and Biliary System  </content>
                                    </paragraph>
                                 </td>
                                 <td>ALT increased, AST increased, bilirubinemia, GGT  </td>
                              </tr>
                              <tr>
                                 <td>
                                    <paragraph>
                                       <content styleCode="bold"/>
                                    </paragraph>
                                    <br/>
                                 </td>
                                 <td>increased, hepatitis, <content styleCode="italics">jaundice, liver failure </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>
                                    <paragraph>
                                       <content styleCode="bold">Metabolic and Nutritional  </content>
                                    </paragraph>
                                 </td>
                                 <td>dehydration  </td>
                              </tr>
                              <tr>
                                 <td>
                                    <paragraph>
                                       <content styleCode="bold">Psychiatric </content>
                                    </paragraph>
                                 </td>
                                 <td>Abnormal dreaming, <content styleCode="italics">alterations in mood (such as mood  </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>
                                    <paragraph>
                                       <content styleCode="bold"/>
                                    </paragraph>
                                    <br/>
                                 </td>
                                 <td>
                                    <content styleCode="italics">elevation),</content> anxiety, appetite increased, confusion, 
</td>
                              </tr>
                              <tr>
                                 <td>
                                    <paragraph>
                                       <content styleCode="bold"/>
                                    </paragraph>
                                    <br/>
                                 </td>
                                 <td>depression, nervousness, somnolence 
</td>
                              </tr>
                              <tr>
                                 <td>
                                    <paragraph>
                                       <content styleCode="bold">Respiratory  </content>
                                    </paragraph>
                                 </td>
                                 <td>asthma, bronchospasm, dyspnea  
</td>
                              </tr>
                              <tr>
                                 <td>
                                    <paragraph>
                                       <content styleCode="bold">Skin and Appendages  </content>
                                    </paragraph>
                                 </td>
                                 <td>alopecia, angioedema, bullous eruption, <content styleCode="italics">erythema</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>
                                    <paragraph>
                                       <content styleCode="bold"/>
                                    </paragraph>
                                    <br/>
                                 </td>
                                 <td>
                                    <content styleCode="italics">multiforme,</content> photosensitivity reaction, pruritus, </td>
                              </tr>
                              <tr>
                                 <td>
                                    <paragraph>
                                       <content styleCode="bold"/>
                                    </paragraph>
                                    <br/>
                                 </td>
                                 <td>
                                    <paragraph>
                                       <content styleCode="italics">exfoliative </content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td>
                                    <paragraph>
                                       <content styleCode="bold"/>
                                    </paragraph>
                                    <br/>
                                 </td>
                                 <td>
                                    <content styleCode="italics">dermatitis, Stevens-Johnson syndrome,</content> sweating </td>
                              </tr>
                              <tr>
                                 <td>
                                    <paragraph>
                                       <content styleCode="bold"/>
                                    </paragraph>
                                    <br/>
                                 </td>
                                 <td>increased, </td>
                              </tr>
                              <tr>
                                 <td>
                                    <paragraph>
                                       <content styleCode="bold"/>
                                    </paragraph>
                                    <br/>
                                 </td>
                                 <td>
                                    <content styleCode="italics">toxic epidermal necrolysis,</content> urticaria </td>
                              </tr>
                              <tr>
                                 <td>
                                    <paragraph>
                                       <content styleCode="bold">Special Senses  </content>
                                    </paragraph>
                                 </td>
                                 <td>abnormal vision, conjunctivitis, taste perversion,  </td>
                              </tr>
                              <tr>
                                 <td>
                                    <paragraph>
                                       <content styleCode="bold"/>
                                    </paragraph>
                                    <br/>
                                 </td>
                                 <td>tinnitus </td>
                              </tr>
                              <tr>
                                 <td>
                                    <paragraph>
                                       <content styleCode="bold">Urinary System  </content>
                                    </paragraph>
                                 </td>
                                 <td>
                                    <content styleCode="italics">acute urinary retention,</content> albuminuria, BUN  </td>
                              </tr>
                              <tr>
                                 <td>
                                    <paragraph>
                                       <content styleCode="bold"/>
                                    </paragraph>
                                    <br/>
                                 </td>
                                 <td>increased, </td>
                              </tr>
                              <tr>
                                 <td>
                                    <paragraph>
                                       <content styleCode="bold"/>
                                    </paragraph>
                                    <br/>
                                 </td>
                                 <td>creatinine increased, hematuria, <content styleCode="italics">interstitial</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>
                                    <paragraph>
                                       <content styleCode="bold"/>
                                    </paragraph>
                                    <br/>
                                 </td>
                                 <td>
                                    <content styleCode="italics">nephritis,</content> renal failure </td>
                              </tr>
                           </tbody>
                        </table>
                        <br/>
                     </text>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="fd37f5f1-45c4-44ac-a79b-b9c74bd235a5"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>OVERDOSAGE</title>
               <text>
                  <paragraph>
                     <linkHtml href=""/>There is limited experience with meloxicam overdose. Four 
cases have taken 6 to 11 times the highest recommended dose; all recovered. 
Cholestyramine is known to accelerate the clearance of meloxicam.</paragraph>
                  <paragraph>Symptoms following acute NSAID overdose are usually limited to lethargy, 
drowsiness, nausea, vomiting, and epigastric pain, which are generally 
reversible with supportive care. Gastrointestinal bleeding can occur. Severe 
poisoning may result in hypertension, acute renal failure, hepatic dysfunction, 
respiratory depression, coma, convulsions, cardiovascular collapse, and cardiac 
arrest. Anaphylactoid reactions have been reported with therapeutic ingestion of 
NSAIDs, and may occur following an overdose.</paragraph>
                  <paragraph>Patients should be managed with symptomatic and supportive care following an 
NSAID overdose. In cases of acute overdose, gastric lavage followed by activated 
charcoal is recommended. Gastric lavage performed more than one hour after 
overdose has little benefit in the treatment of overdose. Administration of 
activated charcoal is recommended for patients who present 1-2 hours after 
overdose. For substantial overdose or severely symptomatic patients, activated 
charcoal may be administered repeatedly. Accelerated removal of meloxicam by 4 
gm oral doses of cholestyramine given three times a day was demonstrated in a 
clinical trial. Administration of cholestyramine may be useful following an 
overdose. Forced diuresis, alkalinization of urine, hemodialysis, or 
hemoperfusion may not be useful due to high protein binding.</paragraph>
               </text>
               <effectiveTime value="20100722"/>
            </section>
         </component>
         <component>
            <section>
               <id root="5f1f4fb9-2210-4201-aa94-b4489e80bf59"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph>Enter section text here</paragraph>
               </text>
               <effectiveTime value="20100722"/>
               <component>
                  <section>
                     <id root="c9dd33be-c96e-499a-abe6-afba07c28e24"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Osteoarthritis and Rheumatoid Arthritis</title>
                     <text>
                        <paragraph>
                           <linkHtml href=""/>Carefully consider the potential benefits and risks of 
meloxicam and other treatment options before deciding to use meloxicam. Use the 
lowest effective dose for the shortest duration consistent with individual 
patient treatment goals (see <content styleCode="bold">
                              <linkHtml href="#ID27">WARNINGS</linkHtml>
                           </content>).</paragraph>
                        <paragraph>After observing the response to initial therapy with meloxicam, the dose 
should be adjusted to suit an individual patient's needs.</paragraph>
                        <paragraph>For the relief of the signs and symptoms of osteoarthritis the recommended 
starting and maintenance oral dose of meloxicam is 7.5 mg once daily. Some 
patients may receive additional benefit by increasing the dose to 15 mg once 
daily. For the relief of the signs and symptoms of rheumatoid arthritis, the 
recommended starting and maintenance oral dose of meloxicam is 7.5 mg once 
daily. Some patients may receive additional benefit by increasing the dose to 15 
mg once daily.</paragraph>
                        <paragraph>The maximum recommended daily oral dose of meloxicam is 15 mg.</paragraph>
                        <paragraph>Meloxicam may be taken without regard to timing of meals.</paragraph>
                     </text>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="676470e5-33bb-46e6-85bf-8c0295665ae7"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>HOW SUPPLIED</title>
               <text>
                  <paragraph>
                     <linkHtml href="#section-"/>Meloxicam Tablets USP are available as light yellow, round, 
flat, uncoated tablets containing meloxicam 7.5 mg or as light yellow, oblong, 
biconvex, uncoated tablets containing meloxicam 15 mg. The 7.5 mg tablet is 
impressed with letter U and L on one side and tablet code 7.5 on the other side. 
The 15 mg tablet is impressed with letter U and L on one side and tablet code 15 
on the other side.</paragraph>
                  <paragraph>
                     <br/>
                  </paragraph>
                  <paragraph>Meloxicam Tablets USP 7.5 mg are available as follows:</paragraph>
                  <table ID="i7ab87690-bf08-47f0-8f19-093f9433e013" width="30%">
                     <tbody>
                        <tr>
                           <td>NDC 54868-5650-4<br/>NDC 54868-5650-6<br/>
                           </td>
                           <td>Bottles of 10<br/>Bottles of 15<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>NDC 54868-5650-5<br/>
                           </td>
                           <td>Bottles of 20<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>NDC 54868-5650-0<br/>
                           </td>
                           <td>Bottles of 30<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>NDC 54868-5650-1<br/>
                           </td>
                           <td>Bottles of 60<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>NDC 54868-5650-3<br/>
                           </td>
                           <td>Bottles of 90<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>NDC 54868-5650-2<br/>
                           </td>
                           <td>Bottles of 100<br/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <br/>
                  <paragraph>Meloxicam Tablets USP 15 mg are available as follows:</paragraph>
                  <table ID="ia58de9b6-126f-4a12-8d05-3d593df6b241" width="30%">
                     <tbody>
                        <tr>
                           <td>NDC 54868-5651-4<br/>NDC 54868-5651-0<br/>
                           </td>
                           <td>Bottles of 15<br/>Bottles of 30<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>NDC 54868-5651-2<br/>
                           </td>
                           <td>Bottles of 60<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>NDC 54868-5651-3<br/>
                           </td>
                           <td>Bottles of 90<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>NDC 54868-5651-1<br/>
                           </td>
                           <td>Bottles of 100<br/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <br/>
               </text>
               <effectiveTime value="20110221"/>
            </section>
         </component>
         <component>
            <section>
               <id root="8d67511d-32d6-4a5b-8d5a-e01e222f6e7e"/>
               <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
               <title>STORAGE AND HANDLING</title>
               <text>
                  <paragraph>
                     <linkHtml href=""/>
                     <content styleCode="bold">Store at Controlled Room Temperature 
20°-25°C (68°-77°F) [See USP]</content>
                  </paragraph>
                  <paragraph>Please address medical inquiries to medical@unichemindia.com</paragraph>
                  <paragraph>
                     <content styleCode="bold">Keep meloxicam tablets in a dry place</content>
                  </paragraph>
                  <paragraph>Dispense tablets in a tight container.</paragraph>
                  <paragraph>Keep this and all medications out of the reach of children.</paragraph>
               </text>
               <effectiveTime value="20100722"/>
               <component>
                  <observationMedia classCode="OBS" moodCode="EVN" ID="MM2">
                     <text>image of Unichem logo</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="Unichem logo.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <section>
                     <id root="3ccd8256-68ce-413c-b782-b96e142b22d7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <linkHtml href=""/>Manufactured by:</paragraph>
                        <paragraph>
                           <content styleCode="bold">UNICHEM LABORATORIES LTD.</content>
                        </paragraph>
                        <paragraph>Pilerne Ind. Estate, </paragraph>
                        <paragraph>Pilerne, Bardez, Goa 403511, India</paragraph>
                        <paragraph>Marketed by :</paragraph>
                        <paragraph>
                           <renderMultiMedia referencedObject="MM2"/>
                        </paragraph>
                        <paragraph>
                           <linkHtml href=""/>Rochelle Park, NJ 07662</paragraph>
                        <paragraph>PSEUSA043-00</paragraph>
                        <paragraph>Revised: January 2009</paragraph>
                        <br/>
                        <paragraph>
                           <br/>
                        </paragraph>
                        <paragraph>Relabeling and Repackaging by:<br/>Physicians Total Care, Inc.<br/>Tulsa, OK      74146<br/>
                        </paragraph>
                     </text>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="75bcec4d-94d6-4f99-aba5-3727c6edfda3"/>
               <code code="42231-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL MEDGUIDE SECTION"/>
               <text>
                  <paragraph>
                     <linkHtml href=""/>
                     <content styleCode="bold">Meloxicam Tablets USP 7.5 mg and 15 
mg</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Medication Guide for Non-Steroidal Anti-Inflammatory Drugs 
(NSAIDs)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">(See the end of this Medication Guide for a list of 
prescription NSAID medicines).</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">What is the most important information I should know about 
medicines called Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)?</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">NSAID medicines may increase the chance of a heart attack or 
stroke that can lead to death. This chance increases:</content>
                  </paragraph>
                  <list listType="unordered" ID="ieed56910-f442-4099-8aeb-f5a4df0d46c6">
                     <item>with longer use of NSAID medicines </item>
                     <item>in people who have heart disease </item>
                  </list>
                  <paragraph>
                     <linkHtml href=""/>
                     <content styleCode="bold">NSAID medicines should never be used right 
before or after a heart surgery called a "coronary artery bypass graft 
(CABG)."</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">NSAID medicines can cause ulcers and bleeding in the stomach 
and intestines at any time during treatment. Ulcers and bleeding:</content>
                  </paragraph>
                  <list listType="unordered" ID="i191824c5-7764-4422-8340-8de5664abc66">
                     <item>can happen without warning symptoms </item>
                     <item>may cause death </item>
                  </list>
                  <paragraph>
                     <linkHtml href=""/>
                     <content styleCode="bold">The chance of a person getting an ulcer or 
bleeding increases with:</content>
                  </paragraph>
                  <list listType="unordered" ID="i345b3961-d9ea-42ae-8c5b-440597d41f42">
                     <item>taking medicines called "corticosteroids" and "anticoagulants" </item>
                     <item>longer use </item>
                     <item>smoking </item>
                     <item>drinking alcohol </item>
                     <item>older age </item>
                     <item>having poor health </item>
                  </list>
                  <paragraph>
                     <linkHtml href=""/>
                     <content styleCode="bold">NSAID medicines should only be 
used:</content>
                  </paragraph>
                  <list listType="unordered" ID="i4395dba8-08d5-4031-840e-3fc76eb07265">
                     <item>exactly as prescribed </item>
                     <item>at the lowest dose possible for your treatment </item>
                     <item>for the shortest time needed </item>
                  </list>
                  <paragraph>
                     <linkHtml href=""/>
                     <content styleCode="bold">What are Non-Steroidal Anti-Inflammatory 
Drugs (NSAIDs)?</content>
                  </paragraph>
                  <paragraph>NSAID medicines are used to treat pain and redness, swelling, and heat 
(inflammation) from medical conditions such as:</paragraph>
                  <list listType="unordered" ID="i03eea96f-ce32-4f35-806e-3b08d0747a10">
                     <item>different types of arthritis </item>
                     <item>menstrual cramps and other types of short-term pain </item>
                  </list>
                  <paragraph>
                     <linkHtml href=""/>
                     <content styleCode="bold">Who should not take a Non-Steroidal 
Anti-Inflammatory Drug (NSAID)?</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Do not take an NSAID medicine:</content>
                  </paragraph>
                  <list listType="unordered" ID="i69c261b5-8c10-4b2c-81bc-4450a7a7b0ce">
                     <item>if you had an asthma attack, hives, or other allergic reaction with aspirin 
or any other NSAID medicine </item>
                     <item>for pain right before or after heart bypass surgery </item>
                  </list>
                  <paragraph>
                     <linkHtml href=""/>
                     <content styleCode="bold">Tell your healthcare provider:</content>
                  </paragraph>
                  <list listType="unordered" ID="i15992de3-f9ed-46e4-8297-0da8d5234c46">
                     <item>about all of your medical conditions </item>
                     <item>about all of the medicines you take. NSAIDs and some other medicines can 
interact with each other and cause serious side effects. <content styleCode="bold">Keep a 
list of your medicines to show to your healthcare provider and pharmacist 
</content>
                     </item>
                     <item>if you are pregnant. NSAID medicines should not be used by pregnant women 
late in their pregnancy </item>
                     <item>if you are breastfeeding. Talk to your doctor </item>
                  </list>
                  <linkHtml href=""/>
                  <table width="100%" ID="i1beed1e6-3a8f-4083-8843-ce848747978c">
                     <col width="100%"/>
                     <thead>
                        <tr>
                           <td>
                              <paragraph>
                                 <content styleCode="bold">What are the possible side effects of 
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)? </content>
                              </paragraph>
                           </td>
                        </tr>
                     </thead>
                     <tbody>
                        <tr>
                           <td>
                              <paragraph>
                                 <content styleCode="bold"/>
                              </paragraph>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <paragraph>
                                 <content styleCode="bold">Serious side effects include: 
</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td>     • heart attack </td>
                        </tr>
                        <tr>
                           <td>     • stroke </td>
                        </tr>
                        <tr>
                           <td>     • high blood pressure </td>
                        </tr>
                        <tr>
                           <td>     • heart failure from body 
swelling (fluid retention) </td>
                        </tr>
                        <tr>
                           <td>     • kidney problems including 
kidney failure </td>
                        </tr>
                        <tr>
                           <td>     • bleeding and ulcers in the 
stomach and intestine </td>
                        </tr>
                        <tr>
                           <td>     • low red blood cells (anemia) 
</td>
                        </tr>
                        <tr>
                           <td>     • life-threatening skin 
reactions </td>
                        </tr>
                        <tr>
                           <td>     • life-threatening allergic 
reactions </td>
                        </tr>
                        <tr>
                           <td>     • liver problems including liver 
failure </td>
                        </tr>
                        <tr>
                           <td>     • asthma attacks in people who 
have asthma </td>
                        </tr>
                        <tr>
                           <td>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <paragraph>
                                 <content styleCode="bold">Other side effects include: 
</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td>     • stomach pain </td>
                        </tr>
                        <tr>
                           <td>     • constipation </td>
                        </tr>
                        <tr>
                           <td>     • diarrhea </td>
                        </tr>
                        <tr>
                           <td>     • gas </td>
                        </tr>
                        <tr>
                           <td>     • heartburn </td>
                        </tr>
                        <tr>
                           <td>     • nausea </td>
                        </tr>
                        <tr>
                           <td>     • vomiting </td>
                        </tr>
                        <tr>
                           <td>     • dizziness 
</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <linkHtml href=""/>
                     <content styleCode="bold">Get emergency help right away if you have 
any of the following symptoms:</content>
                  </paragraph>
                  <list listType="unordered" ID="iba4c790f-b4b6-478f-81d5-cdae779d5151">
                     <item>shortness of breath or trouble breathing </item>
                     <item>chest pain </item>
                     <item>weakness in one part or side of your body </item>
                     <item>slurred speech </item>
                     <item>Swelling of the face or throat </item>
                  </list>
                  <paragraph>
                     <linkHtml href=""/>
                     <content styleCode="bold">Stop your NSAID medicine and call your 
healthcare provider right away if you have any of the following symptoms:</content>
                  </paragraph>
                  <list listType="unordered" ID="i93df59d6-a19a-42da-8bae-b0a3fcd1b833">
                     <item>nausea </item>
                     <item>more tired or weaker than usual </item>
                     <item>itching </item>
                     <item>your skin or eyes look yellow </item>
                     <item>stomach pain </item>
                     <item>flu-like symptoms </item>
                     <item>vomit blood </item>
                     <item>there is blood in your bowel movement or it is black and sticky like tar 
</item>
                     <item>skin rash or blisters with fever </item>
                     <item>unusual weight gain </item>
                     <item>swelling of the arms and legs, hands and feet </item>
                  </list>
                  <paragraph>
                     <linkHtml href=""/>These are not all the side effects with NSAID medicines. 
Talk to your healthcare provider or pharmacist for more information about NSAID 
medicines.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Call your doctor for medical advice about side effects. You 
may report side effects to FDA at 1-800-FDA-1088.</content>
                  </paragraph>
                  <paragraph>Other information about Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)</paragraph>
                  <paragraph>Aspirin is an NSAID medicine but it does not increase the chance of a heart 
attack. Aspirin can cause bleeding in the brain, stomach, and intestines. 
Aspirin can also cause ulcers in the stomach and intestines. Some of these NSAID 
medicines are sold in lower doses without a prescription (over-the-counter). 
Talk to your healthcare provider before using over-the-counter NSAIDs for more 
than 10 days.</paragraph>
                  <paragraph>
                     <content>NSAID medicines that need a prescription</content>
                  </paragraph>
                  <linkHtml href=""/>
                  <table width="100%" ID="i8cb11180-203d-4453-8109-b6badb4599a3">
                     <col width="30%"/>
                     <col width="70%"/>
                     <thead>
                        <tr>
                           <td>
                              <paragraph>
                                 <content styleCode="bold">Generic Name </content>
                              </paragraph>
                           </td>
                           <td>
                              <paragraph>
                                 <content styleCode="bold">Tradename  </content>
                              </paragraph>
                           </td>
                        </tr>
                     </thead>
                     <tbody>
                        <tr>
                           <td>Celecoxib  </td>
                           <td>Celebrex  </td>
                        </tr>
                        <tr>
                           <td>Diclofenac  </td>
                           <td>Cataflam, Voltaren, Arthrotec (combined with misoprostol) </td>
                        </tr>
                        <tr>
                           <td>Diflunisal </td>
                           <td>Dolobid  </td>
                        </tr>
                        <tr>
                           <td>Etodolac </td>
                           <td>Lodine, Lodine XL 
</td>
                        </tr>
                        <tr>
                           <td>Fenoprofen </td>
                           <td>Nalfon, Nalfon 200 
</td>
                        </tr>
                        <tr>
                           <td>Flurbiprofen </td>
                           <td>Ansaid </td>
                        </tr>
                        <tr>
                           <td>Ibuprofen  </td>
                           <td>Motrin, Tab-Profen, Vicoprofen<sup>*</sup> (combined with 
</td>
                        </tr>
                        <tr>
                           <td>
                              <br/>
                           </td>
                           <td>hydrocodone), Combunox (combined with oxycodone) </td>
                        </tr>
                        <tr>
                           <td>Indomethacin </td>
                           <td>Indocin, Indocin SR, Indo-Lemmon, Indomethegan  </td>
                        </tr>
                        <tr>
                           <td>Ketoprofen </td>
                           <td>Oruvail  </td>
                        </tr>
                        <tr>
                           <td>Ketorolac </td>
                           <td>Toradol  </td>
                        </tr>
                        <tr>
                           <td>Mefenamic Acid </td>
                           <td>Ponstel  </td>
                        </tr>
                        <tr>
                           <td>Meloxicam </td>
                           <td>Mobic  </td>
                        </tr>
                        <tr>
                           <td>Nabumetone </td>
                           <td>Relafen  </td>
                        </tr>
                        <tr>
                           <td>Naproxen </td>
                           <td>Naprosyn, Anaprox, Anaprox DS, EC-Naprosyn, Naprelan,  </td>
                        </tr>
                        <tr>
                           <td>
                              <br/>
                           </td>
                           <td>PREVACID NapraPAC (copackaged with lansoprazole) </td>
                        </tr>
                        <tr>
                           <td>Oxaprozin </td>
                           <td>Daypro </td>
                        </tr>
                        <tr>
                           <td>Piroxicam </td>
                           <td>Feldene </td>
                        </tr>
                        <tr>
                           <td>Sulindac </td>
                           <td>Clinoril </td>
                        </tr>
                        <tr>
                           <td>Tolmetin </td>
                           <td>Tolectin, Tolectin DS, Tolectin 600  </td>
                        </tr>
                     </tbody>
                  </table>
                  <linkHtml href=""/>
                  <linkHtml href=""/>
                  <paragraph>
                     <linkHtml href=""/>*  Vicoprofen contains the same dose of ibuprofen as over-the counter ( OTC ) 
NSAIDS, and is usually used for less than 10 days to treat pain. The OTC NSAID 
label warns that long term continuous use may increase the risk of heart attack 
or stroke.</paragraph>
                  <paragraph>Manufactured by:</paragraph>
                  <paragraph>
                     <content styleCode="bold">UNICHEM LABORATORIES LTD.</content>
                  </paragraph>
                  <paragraph>Pilerne Ind. Estate,</paragraph>
                  <paragraph>Pilerne, Bardez, Goa 403511, India</paragraph>
                  <paragraph>Marketed by:</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM3"/>
                  </paragraph>
                  <paragraph>
                     <linkHtml href=""/>Rochelle Park, NJ 07662</paragraph>
                  <paragraph>
                     <content styleCode="italics">This Medication Guide has been approved by the U.S. Food 
and Drug Administration</content>
                  </paragraph>
                  <paragraph>PSEUSA044A-00</paragraph>
                  <paragraph>Revised: January 2009</paragraph>
               </text>
               <effectiveTime value="20100722"/>
               <component>
                  <observationMedia classCode="OBS" moodCode="EVN" ID="MM3">
                     <text>image of Unichem logo</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="Unichem logo.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="5c0592fe-0310-4673-8812-2bff8e7cb616"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <paragraph>Meloxicam Tablets USP <br/>
                  </paragraph>
                  <paragraph>7.5 mg</paragraph>
                  <renderMultiMedia referencedObject="MM4"/>
                  <paragraph>
                     <br/>
                  </paragraph>
                  <paragraph>Meloxicam Tablets USP <br/>
                  </paragraph>
                  <paragraph>15 mg</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM5"/>
                  </paragraph>
               </text>
               <effectiveTime value="20100722"/>
               <component>
                  <observationMedia classCode="OBS" moodCode="EVN" ID="MM4">
                     <text>image of 7.5 mg package label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="package label 01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia classCode="OBS" moodCode="EVN" ID="MM5">
                     <text>image of 15 mg package label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="package label 02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>